American Well Corp (AMWL)
Health Care · Health Care Technology / Telehealth · NYSE
Amwell provides an enterprise-grade digital care platform and SaaS solutions that help healthcare providers and payers manage and coordinate hybrid virtual and in-person care programs.
What American Well Corp does
Amwell is an enterprise platform and software-as-a-service company that enables hybrid care delivery across in-person, virtual, and automated settings. It provides health systems and health plans with a digital care operating system for managing patient outcomes, clinical operations, and care coordination under their own brands. Additionally, the company offers Carepoint hardware for hospital and home settings and provides clinical services through its affiliated medical group, AMG.
Recent developments
The company raised the low end of its 2026 revenue guidance to a range of $200 million to $205 million and improved its Adjusted EBITDA outlook. Amwell announced it is positioned to become a prime contractor for the Defense Health Agency and projects achieving positive cash flow from operations in Q4 2026.
From American Well Corp's filing of 2026-08-04.
Themes: digital health, telehealth, hybrid care delivery, health tech SaaS, AI-powered care, care coordination
Fundamentals
- Price$13.20 as of 2026-10-20 close
- Market cap$225M as of 2026-07-24 (share count; price 2026-10-20)
- 1-year return+135.3% 2025-10-20 close $5.61 → 2026-10-20 close $13.20
- P/En/a negative earnings
- Net margin-38.4% FY2025, SEC XBRL
- ROE-38.6% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)-2.0% FY2025, SEC XBRL
- Revenue CAGR (3y)-3.5% SEC XBRL
- Beta1.17 as of 2026-09-03
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How AMWL compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $52M | -$10M | -$10M | -$0.59 | $11M† | $8000† |
| Q1 FY2026 2026-03-31 | $55M | -$17M | -$11M | -$0.66 | -$983000 | $5000 |
| Q4 FY2025 2025-12-31 | $55M† | -$25M† | -$25M† | -$1.52† | -$17M† | $12000† |
| Q3 FY2025 2025-09-30 | $56M | -$29M | -$32M | -$2.00 | -$19M† | $0† |
| Q2 FY2025 2025-06-30 | $71M | -$20M | -$20M | -$1.24 | -$5M† | $0† |
| Q1 FY2025 2025-03-31 | $67M | -$30M | -$19M | -$1.19 | -$25M | $9000 |
| Q4 FY2024 2024-12-31 | $71M† | -$43M† | -$43M† | -$2.75† | -$13M† | $3000† |
| Q3 FY2024 2024-09-30 | $61M | -$47M | -$43M | -$2.87 | -$32M† | $15000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$196M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How American Well Corp looks technically
American Well Corp (AMWL) is trading 54.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 117 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 54.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +54.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.70 | $12.70 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $8.52 | $8.52 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 11.99. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 117 trading days ago — a "golden cross", a bullish long-term signal | 117 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend) | 11.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30) | 55.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($11.17 to $13.79) — its "stochastic" reading is 77 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 77.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 20 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $14.19 | $14.19 |
|---|---|---|
| From the 52-week high | it is 7.0% below its 52-week high (its highest price of the past year) | -7.0% |
| Above the 52-week low | it is 255.8% above its 52-week low (its lowest price of the past year) | +255.8% |
| Below the 52-week high | it is 7.0% below its highest point of the past year | 7.0% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 27 trading days ago | 27 sessions |
| All-time high | its highest closing price on record is $875.00 (set on 2021-01-27) | $875.00 |
| Given back of the 52-week move | over the past year its closes ranged ($3.78 to $13.87), and it has given back only a small part of its rise from last year’s low — 7% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.31 to $7.63. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 6.6% |
| From the all-time high | it is 98.5% below its all-time high | -98.5% |
| Nearest price level | it is trading 7.3% below a resistance level at $14.16 — a price it turned at twice since 2026-08-05, most recently on 2026-09-14. Since 2024-10-21 it has 16 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +7.3% |
| All-time low | its lowest closing price on record is $3.71 (set on 2025-11-21) | $3.71 |
| Above the all-time low | it is 255.8% above its all-time low | +255.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 88% of it) | 12th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7856 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7856 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $11.70 and $13.77 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $11.70 – $12.73 – $13.77 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 6.0 daily ranges above its 200-day average price (54.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.17× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.7% |
|---|---|---|
| Open gap | it gapped 7.3% above the previous close 53 sessions ago and has not traded back through the level it left behind at 10.42 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +7.3% |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +13.01% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 5.0 percentage points (the stock lost 4.0% while the market gained 1.0%) | -5.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 1.3 percentage points (the stock gained 4.9% while the market gained 3.6%) | +1.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 91.2 percentage points (the stock gained 99.7% while the market gained 8.5%) | +91.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 120.7 percentage points (the stock gained 135.3% while the market gained 14.6%) | +120.7% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.5% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 10.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +3.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 45% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $9.12 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | +44.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $12.75 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | +3.5% |
Double top, bearish — forming · entry $11.66 · 50 sessions in
Rising wedge, bearish — broke down · entry $13.44 · 84 sessions in
Price levels it has turned at before
AMWL last closed at $13.20 on 2026-10-20. Since 2024-10-21 it has turned at 16 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $14.16 | Resistance | 7.3% above the last close | turned there twice · 2026-08-05 to 2026-09-14 |
| $11.99 | Support | 9.1% below the last close | turned there twice · 2025-01-30 to 2026-10-02 |
| $11.29 | Support | 14.4% below the last close | turned there twice · 2025-01-21 to 2026-08-25 |
| $9.99 | Support | 24.3% below the last close | turned there four times · 2024-12-10 to 2026-08-04 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $11.99.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 2 trading days, since 2026-10-19.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Broke down to a new 20-day low · trendless / choppy (low ADX) · beating the market · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.71 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$12.80 range $11.00 – $16.00; median $12.00
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AMWL
- Consensus EPS estimate-$0.66 next reporting period, as of 2026-10-18
- Estimate change, 30 days$0.00 from -$0.66, on 2026-09-14, 34-day window
- Readings revised upward0% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The digital care market is evolving, volatile, and faces uncertainty regarding consumer adoption and sustained demand.","The company faces intense competition from established digital care players, major technology companies, and EHR providers, which exerts pricing pressure.","Revenue is dependent on healthcare industry spending, regulations, and reimbursement policies, which are subject to legislative changes."]
What changed in the latest 10-Q
AI-assisted comparison of AMWL's 10-Q filed 2026-08-04 against the prior one filed 2026-05-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-04) states the Defense Health Agency relationship continuation risk refers to 'beyond the third quarter of 2026' instead of 'beyond July 2026'.
- Removed:
- Older filing (2026-05-05) states the Defense Health Agency relationship continuation risk refers to 'beyond July 2026 with comparable financial terms', which was removed in the newer filing.
- Reworded:
- Newer filing (2026-08-04) updates the virtual care visit metric to 'approximately 39.5 million virtual care visits... including approximately 1.9 million in the six months ended June 30, 2026'; older filing (2026-05-05) states 'approximately 38.7 million virtual care visits... including approximately 1.1 million in the three months ended March 31, 2026'.
- Defense Health Agency risk factor wording changed from 'beyond July 2026' (older filing, 2026-05-05) to 'beyond the third quarter of 2026' (newer filing, 2026-08-04).
- Notes:
- The newer filing text is truncated at the end of the 'Our Business Model' section, so any changes after that point cannot be assessed.
- The newer filing page break shows '18' and the older filing shows '17', but this is not a substantive text change.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 7 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 4 sells ($260702) — 4 selling insiders
- Last 90 days · read to 2026-10-160 buys · 7 sells ($431047) — 4 selling insiders
- Last 180 days · read to 2026-10-161 buy ($4938) · 15 sells ($844630) — 1 buying, 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-01. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AMWL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AMWL as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,095,610
- Reported value $9,991,964
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AMWL's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AMWL had 172,452 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for AMWL because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 172,452
- Prior settlement (shares) 160,460
- Reported change 7.47%
- Days to cover (reported) 1.82
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Teladoc Health (TDOC)
- Included Health
- MDLive
- Zoom Video Communications (ZM)
- Microsoft Teams (MSFT)
- Doximity (DOCS)
- Amazon (AMZN)
- Epic Systems
- Oracle Health (Cerner)
- athenahealth
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AMWL vs…
American Well Corp is found in…
Frequently asked questions
What does American Well Corp (AMWL) do?
Amwell is an enterprise platform and software-as-a-service company that enables hybrid care delivery across in-person, virtual, and automated settings. It provides health systems and health plans with a digital care operating system for managing patient outcomes, clinical operations, and care coordination under their own brands. Additionally, the company offers Carepoint hardware for hospital and home settings and provides clinical services through its affiliated medical group, AMG.
What sector is American Well Corp (AMWL) in?
American Well Corp (AMWL) is classified in the Health Care sector. Its industry is Health Care Technology / Telehealth. It trades on NYSE.
Who are American Well Corp's (AMWL) competitors?
Notable peers of American Well Corp (AMWL) include Teladoc Health, Included Health, MDLive, Zoom Video Communications and Microsoft Teams. This peer set is informational only — not financial advice.
Is American Well Corp (AMWL) overbought or oversold right now?
American Well Corp (AMWL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 56, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AMWL come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.